慢性粒细胞白血病对BCR-ABL酪氨酸激酶靶向抑制剂的耐药机制  

Mechanism of drug resistance for chronic myeloid leukemia to BCR-ABL tyrosine kinase inhibitor

作　　者：肖宇航[1,2] 秦群[1] 

机构地区：[1]中南大学湘雅医院药剂科,长沙410008 [2]中南大学药学院,长沙410013

出　　处：《国际病理科学与临床杂志》2009年第6期524-528,共5页Journal of International Pathology and Clinical Medicine

摘　　要：BCR-ABL酪氨酸激酶抑制剂靶向治疗慢性粒细胞白血病(chronic myeloid leukemia,CML)能够达到良好的临床效应,然而随着其临床广泛应用,对其产生耐药逐渐增多。CML细胞多药耐药是目前导致化疗失败,缓解率降低,疾病复发的主要原因。本文就CML对BCR-ABL酪氨酸激酶靶向抑制剂耐药的主要机制进行了阐述。Targeted therapy of chronic myeloid leukemia （CML） with BCR-ABL tyrosine kinase inhibitor shows a very good clinical therapeutic effect, but the drug resistance phenomena are increased with the wide use of tyrosine kinase inhibitor in clinic. Muhidrug resistance is the main reason of chemotherapy failure for CML patients accompanied by the decrease in remission rate and the increase in relapse rate. This review focus on the recent progress in the drug resistant mechanism for BCR-ABL tyrosine kinase inhibitor.

关 键 词：慢性粒细胞白血病 BCR—ABL酪氨酸激酶抑制剂 多药耐药 

分 类 号：R733.72[医药卫生—肿瘤]